The Synthesis/Medicinal Chemistry Core (SynCore) will provide enabling technology vital to this NOVEL SMALL-MOLECULE THERAPIES FOR CF program project. The overall goal of this program is the discovery of novel CF-relevant small-molecules which serve as potentiators of mutant CFTRs, correctors deltaF508-CFTR cellular misprocessing, CFTR inhibitors, enhancers of non-viral gene delivery, resources for correlation between nasal PDs and chloride transport cultured cells from CF subjects, antimicrobials, aquaporin-based enhancers of gland fluid secretion, CFTR activators to enhance alveolar fluid clearance, inhibitors of glandular mucin secretion, resources to chronically inhibit CFTR function in pigs, reagents useful in defining the role of ASL in innate immune defense in CF, reagents useful in defining the role of defective airway submucosal gland secretion in CF lung disease, and hit-to-lead discovery libraries for high-throughput screening. SynCore will figure prominently in this program's efforts to realize these objectives by preparing lead discovery libraries designed to explore hits provide by high-throughput screening and providing study-relevant quantities of the lead compounds required for the studies outlined in the PROJECTs2. The SynCore specific aims are to (1) prepare chemically pure, structurally characterized small-molecule HIT and LEAD compounds for application by the PROJECTS and the COREs and (2) prepare hit-to-lead discovery libraries designed to structurally explore hits identified by high-throughput screening.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
1P30DK072517-01
Application #
7052597
Study Section
Special Emphasis Panel (ZDK1-GRB-6 (M1))
Project Start
2005-07-01
Project End
2010-06-30
Budget Start
2005-07-01
Budget End
2006-07-31
Support Year
1
Fiscal Year
2005
Total Cost
$148,925
Indirect Cost
Name
University of California San Francisco
Department
Type
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Sun, Dingyuan I; Tasca, Alexia; Haas, Maximilian et al. (2018) Na+/H+ Exchangers Are Required for the Development and Function of Vertebrate Mucociliary Epithelia. Cells Tissues Organs :1-14
Bhakta, Nirav R; Christenson, Stephanie A; Nerella, Srilaxmi et al. (2018) IFN-stimulated Gene Expression, Type 2 Inflammation, and Endoplasmic Reticulum Stress in Asthma. Am J Respir Crit Care Med 197:313-324
Smith, Alex J; Verkman, Alan S (2018) The ""glymphatic"" mechanism for solute clearance in Alzheimer's disease: game changer or unproven speculation? FASEB J 32:543-551
Duan, Tianjiao; Smith, Alex J; Verkman, Alan S (2018) Complement-dependent bystander injury to neurons in AQP4-IgG seropositive neuromyelitis optica. J Neuroinflammation 15:294
Lee, Sujin; Cil, Onur; Diez-Cecilia, Elena et al. (2018) Nanomolar-Potency 1,2,4-Triazoloquinoxaline Inhibitors of the Kidney Urea Transporter UT-A1. J Med Chem 61:3209-3217
Tradtrantip, Lukmanee; Felix, Christian M; Spirig, Rolf et al. (2018) Recombinant IgG1 Fc hexamers block cytotoxicity and pathological changes in experimental in vitro and rat models of neuromyelitis optica. Neuropharmacology 133:345-353
Phuan, Puay-Wah; Veit, Guido; Tan, Joseph-Anthony et al. (2018) ?F508-CFTR Modulator Screen Based on Cell Surface Targeting of a Chimeric Nucleotide Binding Domain 1 Reporter. SLAS Discov 23:823-831
Verkman, Alan S; Yao, Xiaoming; Smith, Alex J (2018) The evolving mystery of why skeletal muscle is spared in seropositive neuromyelitis optica. J Cell Mol Med 22:2039-2040
Verkman, Alan S; Smith, Alex J; Phuan, Puay-Wah et al. (2017) The aquaporin-4 water channel as a potential drug target in neurological disorders. Expert Opin Ther Targets 21:1161-1170
Zhu, Jie S; Son, Jung-Ho; Teuthorn, Andrew P et al. (2017) Diverting Reactive Intermediates Toward Unusual Chemistry: Unexpected Anthranil Products from Davis-Beirut Reaction. J Org Chem 82:10875-10882

Showing the most recent 10 out of 276 publications